Y-M M Park1, D B Bookwalter2, K M O'Brien3, C L Jackson4, C R Weinberg5, D P Sandler6. 1. Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, USA. Electronic address: mark.park@nih.gov. 2. Westat, Durham, USA. 3. Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, USA. 4. Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, USA; Intramural Program, National Institute on Minority Health and Health Disparities, National Institutes of Health, Department of Health and Human Services, Bethesda, USA. 5. Biostatistics & Computational Biology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, USA. 6. Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, USA. Electronic address: sandler@niehs.nih.gov.
Abstract
BACKGROUND: Type 2 diabetes (T2D) has been associated with increased breast cancer risk, but commonly prescribed antidiabetic medications such as metformin may reduce risk. Few studies have investigated T2D and medications together in relation to breast cancer. PATIENTS AND METHODS: Data came from 44 541 Sister Study participants aged 35 to 74 years at enrollment (2003-2009) who satisfied eligibility criteria, followed through 15 September 2017. Information on time-varying, self-reported, physician-diagnosed, prevalent and incident T2D, use of antidiabetic medications, and covariates was obtained from baseline and follow-up questionnaires. Incident breast cancers were confirmed with medical records. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated. RESULTS: During follow-up (median, 8.6 years), 2678 breast cancers were diagnosed at least 1 year after enrollment. There were 3227 women (7.2%) with prevalent and 2389 (5.3%) with incident T2D, among whom 61% (n = 3386) were ever treated with metformin. There was no overall association between T2D and breast cancer risk (HR 0.99; 95% CI, 0.87-1.13). However, T2D was associated with increased risk of triple-negative breast cancer (HR 1.40; 95% CI, 0.90-2.16). Compared with not having T2D, T2D with metformin use was not associated with overall breast cancer risk (HR 0.98; 95% CI, 0.83-1.15), but it was associated with decreased risk of estrogen receptor (ER)-positive breast cancer (HR 0.86; 95% CI 0.70-1.05) and increased risk of ER-negative (HR 1.25; 95% CI, 0.84-1.88) and triple-negative breast cancer (HR 1.74; 95% CI, 1.06-2.83). The inverse association with ER-positive cancer was stronger for longer duration (≥10 year) metformin use (HR 0.62; 95% CI, 0.38-1.01; P for trend = 0.09). Results were supported by sensitivity analyses. CONCLUSION: Our findings suggest that associations between T2D and breast cancer may differ by hormone receptor status and that associations between T2D and ER-positive breast cancer may be reduced by long-term metformin use. Published by Elsevier Ltd.
BACKGROUND: Type 2 diabetes (T2D) has been associated with increased breast cancer risk, but commonly prescribed antidiabetic medications such as metformin may reduce risk. Few studies have investigated T2D and medications together in relation to breast cancer. PATIENTS AND METHODS: Data came from 44 541 Sister Study participants aged 35 to 74 years at enrollment (2003-2009) who satisfied eligibility criteria, followed through 15 September 2017. Information on time-varying, self-reported, physician-diagnosed, prevalent and incident T2D, use of antidiabetic medications, and covariates was obtained from baseline and follow-up questionnaires. Incident breast cancers were confirmed with medical records. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated. RESULTS: During follow-up (median, 8.6 years), 2678 breast cancers were diagnosed at least 1 year after enrollment. There were 3227 women (7.2%) with prevalent and 2389 (5.3%) with incident T2D, among whom 61% (n = 3386) were ever treated with metformin. There was no overall association between T2D and breast cancer risk (HR 0.99; 95% CI, 0.87-1.13). However, T2D was associated with increased risk of triple-negative breast cancer (HR 1.40; 95% CI, 0.90-2.16). Compared with not having T2D, T2D with metformin use was not associated with overall breast cancer risk (HR 0.98; 95% CI, 0.83-1.15), but it was associated with decreased risk of estrogen receptor (ER)-positive breast cancer (HR 0.86; 95% CI 0.70-1.05) and increased risk of ER-negative (HR 1.25; 95% CI, 0.84-1.88) and triple-negative breast cancer (HR 1.74; 95% CI, 1.06-2.83). The inverse association with ER-positive cancer was stronger for longer duration (≥10 year) metformin use (HR 0.62; 95% CI, 0.38-1.01; P for trend = 0.09). Results were supported by sensitivity analyses. CONCLUSION: Our findings suggest that associations between T2D and breast cancer may differ by hormone receptor status and that associations between T2D and ER-positive breast cancer may be reduced by long-term metformin use. Published by Elsevier Ltd.
Entities:
Keywords:
antidiabetic medication; breast cancer; estrogen receptor; metformin; triple-negative; type 2 diabetes
Authors: Maureen Sanderson; Loren Lipworth; Martha J Shrubsole; Shaneda Warren Andersen; Xiao-Ou Shu; Wei Zheng; Margaret K Hargreaves; William J Blot Journal: Cancer Causes Control Date: 2019-04-02 Impact factor: 2.506
Authors: Sabina Sieri; Paola Muti; Agnoli Claudia; Franco Berrino; Valeria Pala; Sara Grioni; Carlo Alberto Abagnato; Giovanni Blandino; Paolo Contiero; Holger J Schunemann; Vittorio Krogh Journal: Int J Cancer Date: 2011-05-25 Impact factor: 7.396
Authors: Fernando Lara-Medina; Víctor Pérez-Sánchez; David Saavedra-Pérez; Monika Blake-Cerda; Claudia Arce; Daniel Motola-Kuba; Cynthia Villarreal-Garza; Ana Maria González-Angulo; Enrique Bargalló; Jose Luis Aguilar; Alejandro Mohar; Óscar Arrieta Journal: Cancer Date: 2011-03-08 Impact factor: 6.860
Authors: Karin B Michels; Caren G Solomon; Frank B Hu; Bernard A Rosner; Susan E Hankinson; Graham A Colditz; JoAnn E Manson Journal: Diabetes Care Date: 2003-06 Impact factor: 19.112
Authors: Aimee A D'Aloisio; Hazel B Nichols; M Elizabeth Hodgson; Sandra L Deming-Halverson; Dale P Sandler Journal: BMC Cancer Date: 2017-10-23 Impact factor: 4.430
Authors: Mary V Diaz-Santana; Katie M O'Brien; Yong-Moon Mark Park; Dale P Sandler; Clarice R Weinberg Journal: Diabetes Care Date: 2022-04-01 Impact factor: 17.152